Category - Developments

Developments

Tenax posts positive Phase 2 levosimendan data

Tenax Therapeutics (NASDAQ:TENX) reported positive results from a Phase 2 trial evaluating levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH...

June 4, 2020

Developments

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC)...

June 4, 2020

Developments

Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

Menlo Therapeutics (NASDAQ:MNLO) reported positive results from its Phase 2 trial evaluating FCD105 or the treatment of moderate-to-severe acne vulgaris. The study enrolled 447 patients who received either FCD105, a 3%...

June 4, 2020

Developments

PharmAust lab tests show positive signs for suppressing COVID-19

PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...

June 4, 2020

Developments

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

June 1, 2020

Developments

Menlo Therapeutics ZILXI gets FDA approval for rosacea

Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...

May 29, 2020

Developments

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer. In the primary endpoint responder analysis, 97% of men...

May 29, 2020

Developments

AVEO Oncology reports positive overall survival results from Phase 3 RCC study

AVEO Oncology (NASDAQ:AVEO) reported positive final overall survival results from its Phase 3 TIVO-3 trial comparing tivozanib to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The trial met the...

May 29, 2020

Developments

Repare Therapeutics in research collaboration with Bristol Myers

Closely-held Repare Therapeutics inked an exclusive, worldwide research collaboration with Bristol Myers Squibb (NYSE:BMY). Under the accord, the companies will leverage Repare’s CRISPR-enabled genome-wide synthetic...

May 28, 2020

Developments

Cardiff Oncology onvansertib gets FDA fast track designation for colorectal cancer

Cardiff Oncology’s (NASDAQ:CRDF) onvansertib received FDA fast track designation for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The company is currently assessing...

May 28, 2020

Category - Developments

Subscribe